Translational potential of γδ T cells in hematologic diseases: from immunobiology to therapeutic innovation

persistence, subset exhaustion, and manufacturing variability-and discuss rational engineering strategies, metabolic preconditioning, and epigenetic modulation as solutions. Ultimately, advancing γδ T cell therapies requires overcoming these hurdles to transition them effectively from the bench to mainstream clinical practice.